ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1703	National Cancer Institute	Html	en	Tumor Grade	A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.	Gleason score 0.401724 NCI fact sheet 0.404685 lower grade 0.405507 tissue organization 0.400496 better prognosis 0.354968 tumor tissue 0.703634 type-specific grading systems 0.412132 tumor type 0.491464 cancer cells 0.405656 biopsied tissue 0.413701 Gleason scores 0.355221 primary brain tumors 0.42294 tumor size 0.501863 abnormal-looking cells 0.400459 Nottingham grading 0.360235 higher-grade cancer 0.364598 tumor cells 0.631844 normal cells 0.49423 nearby lymph nodes 0.408457 tumor grade 0.785451 regional lymph node 0.409603 secondary pattern 0.388809 breast tumors 0.384185 Scarff-Bloom-Richardson grading 0.361738	normal tissue structures 0.487646 primary pattern 0.353415 microscopic examination 0.353649 breast cancer 0.39308 biopsy samples 0.354483 Staging page 0.357155 microscopic appearance 0.359178 different types 0.358151 tumors 0.490957 prostate cancer 0.440387 cancer staging 0.368981 slower rate 0.360886 American Joint Committee 0.39399 tumor 0.981653 tumor grades 0.501473 common tissue pattern 0.44497 cancer 0.557882 total score 0.354108 soft tissue sarcoma 0.443518 prostate cancers 0.367392 Gleason scoring 0.35738 tumor tissue look 0.635152 cancer stage 0.457333	CLICK HERE
1806	National Cancer Institute	Html	es	Tratamiento del cáncer de estómago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de estómago.	after d2 gastrectomy 0.313513 gastrectomía d2 0.31496 Cunningham D 0.34388 Macdonald JS 0.318723 Chemoradiotherapy after surgery 0.344328 randomised controlled 0.319618 combined modality therapy 0.360634 mejoría significativa 0.31176 Stenning SP 0.310838 intergroup trial calgb 0.31542 Postoperative adjuvant chemoradiation 0.322032 after ci 5-fu 0.317294 fase iii 0.364462 Estados Unidos 0.347269 with s-1 0.314235 randomized trial comparing 0.314288 quimiorradioterapia posoperatoria 0.360835 ensayo rtog-9904 0.324678 patients with 0.484752 adyuvante versus tasa 0.360686 supportive care 0.325372 Clinical Oncology 0.311085 Perioperative chemotherapy versus 0.334581 chemotherapy plus best 0.312401 Smalley SR 0.318682	with surgery 0.339493 Ajani JA 0.354002 or gastroesophageal junction 0.340588 ensayo swog-s0425 0.324881 Allum WH 0.311046 quimiorradioterapia adyuvante versus 0.364135 estadio ib 0.338006 gastrectomía curativa d2 0.319296 Van Cutsem E 0.313883 Benedetti J 0.318647 quimioterapia perioperatoria 0.352185 gastric carcinoma 0.325701 gastric cancer 0.935626 Clin Oncol 0.612714 or gastro-oesophageal junction 0.317111 trial comparing 0.314461 supportive care with 0.324232 Winter K 0.319459 Gastric Cancer Study 0.317632 chemotherapy versus surgery 0.338116 grupo s-1 0.317965 Okawara GS 0.319919 care with best 0.314996 quimioterapia posoperatoria 0.31518	CLICK HERE
1871	National Cancer Institute	Html	es	Tratamiento del carcinoma de sitio primario desconocido (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del carcinoma de sitio primario desconocido.	cáncer epitelial versus 0.404134 Greco FA 0.432795 unknown primary tumours 0.414817 cisplatin-based combination chemotherapy 0.404363 unknown primary site 0.721557 Pavlidis N 0.405224 Breast carcinoma presenting 0.411406 unknown primary origin 0.450607 Hainsworth JD 0.442528 Metastatic malignant melanoma 0.405856 Cancer Res 0.404192 Radiat Oncol Biol 0.414855 neuroendocrine carcinoma 0.415368 Natl Cancer Inst 0.417117 poorly differentiated 0.438667 Melanoma from unknown 0.410685 serous papillary carcinoma 0.405287 patients with 0.456873 gene expression profiling 0.404698 unknown primary carcinoma 0.451216 carcinoma nasofaríngeo 0.409399 poorly differentiated carcinoma 0.41977 cervical lymph 0.404293 patients with unknown 0.4336 Rodriguez E 0.405003	presenting as axillary 0.404521 metastases from unknown 0.428245 Unknown primary melanoma 0.416245 Abbruzzese MC 0.404845 Curr Probl Cancer 0.404442 primary neoplasm 0.406005 or undiscovered primary 0.406863 from unknown primary 0.455678 primary tumor site 0.417993 Surg Oncol 0.405079 PDQ Tratamiento 0.416061 Intern Med 0.413673 nasopharyngeal carcinoma 0.405469 Clin Oncol 0.44391 Johnson DH 0.404766 unknown primary 0.993061 Oncol Biol Phys 0.415244 with unknown primary 0.46599 metastatic adenocarcinomas 0.408539 unknown primary tumor 0.442645 germ cell tumors 0.405207 carcinoma presenting as 0.411228 occult primary carcinoma 0.410287 cancer incidence 0.406991	CLICK HERE
1875	National Cancer Institute	Html	es	Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida.	aids-related non-hodgkin lymphomas 0.608138 non-hodgkin's lymphomas 0.666621 prognostic factors 0.350902 HIV-associated Hodgkin 0.399104 Spina M 0.351065 linfoma hodgkin 0.348723 Epstein-Barr virus 0.393918 atypical burkitt lymphoma 0.351153 large b-cell lymphoma 0.344814 HIV-related lymphoma 0.343107 immunodeficiency virus 0.402901 highly active 0.512378 human immunodeficiency virus-associated 0.403779 Burkitt lymphoma 0.387609 immunodeficiency virus-associated non-Hodgkin 0.342734 AIDS patients with 0.376046 Dunleavy K 0.344239 Natl Cancer Inst 0.464946 active antiretroviral therapy 0.726916 central nervous system 0.649203 human immunodeficiency virus-related 0.374511 HIV-infected patients with 0.343338 immunodeficiency syndrome-related lymphoma 0.354213 lymphoma treated with 0.43581 patients with 0.924942	patients with primary 0.375652 chemotherapy with 0.357715 human immunodeficiency 0.754154 patients with aids-related 0.424038 oral t-cell lymphoma 0.346331 acquired immunodeficiency syndrome-related 0.357324 lymphoma is dramatically 0.348699 immunodeficiency virus-related lymphoma 0.359105 acquired immunodeficiency 0.378848 aids-related lymphoma 0.736141 treatment with 0.389583 primary central nervous 0.521797 Intern Med 0.353617 Clin Oncol 0.792214 sistema nervioso central 0.421872 systemic aids-related non-hodgkin 0.367456 non-hodgkin lymphoma 0.744829 Hodgkin lymphoma treated 0.362251 study with 0.356196 hiv-associated lymphomas 0.544837 primary effusion lymphoma 0.456053 nervous system lymphoma 0.736571 células b 0.35592 AIDS-related primary lymphoma 0.361221	CLICK HERE
1943	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.	pleural catheter 0.17861 Ripamonti C 0.130559 dificultad respiratoria 0.26023 malignant effusion 0.115362 lung cancer 0.190962 Sin embargo 0.114284 end-of-life patients with 0.119385 indwelling pleural catheter 0.162022 Dudgeon DJ 0.13043 fármacos pleurales esclerosantes 0.112004 disfunción muscular respiratoria 0.121219 Hematol Oncol Clin 0.143013 hypoxemic patients with 0.118489 patients receiving chemotherapy 0.111162 Cancer Organisation Thoracic 0.117844 antitusivos opioides 0.112496 recurrent symptomatic malignant 0.110714 patients with 0.625852 insuficiencia cardiaca 0.134239 Pain Symptom Manage 0.478956 randomized controlled 0.112081 pleural fluid 0.136904 Cancer Dyspnea Scale 0.146703 Moroni M 0.110841 Care Cancer 0.128094	pleural catheter vs 0.135869 Physiol Neurobiol 0.116436 as symptomatic treatment 0.110943 derrame maligno fracasa 0.114534 obstructiva crónica 0.135859 vías respiratorias 0.205286 tunnelled pleural catheter 0.139919 tos crónica causa 0.111919 prospective randomized 0.110614 pleural effusions with 0.149859 Intern Med 0.132242 Clin Oncol 0.11762 Med Pediatr Oncol 0.111608 Clin North Am 0.136363 Bruera E 0.203018 systematic review 0.116364 Oncol Clin North 0.140711 American Thoracic Society 0.114142 as palliative treatment 0.110799 malignant pleural effusions 0.900896 Crit Care Med 0.171232 symptomatic malignant 0.122652 alone versus 0.11566 compared with 0.110951	CLICK HERE
2082	National Cancer Institute	Html	en	Cancer Clusters	A fact sheet that describes what constitutes a cancer cluster and the process for reporting and investigating suspected clusters.	major risk factor 0.385962 specific environmental hazards 0.38074 rare cancer 0.409989 website uses data 0.380594 cancer trends 0.398646 individual cancer clusters 0.469731 number 0.405815 investigators 0.393508 Health Hazard Evaluation 0.380995 Disease Control 0.519415 Health Consultations page 0.381331 cancer cluster 0.895701 cancer clusters 0.841764 National Center 0.381056 ATSDR regional offices 0.380684 different geographic area 0.38274 cluster investigations 0.411002 true cancer clusters 0.482566 public health assessments 0.472612 statistically significant difference 0.384068 vinyl chloride 0.380035 specific cancer type 0.434002 primary cancer 0.413707 U.S. Census Bureau 0.37492 specific hazardous substances 0.37613	different cancer types 0.429181 state health department 0.450442 total number 0.385248 cancer cases 0.749447 health departments 0.457783 NCI analyze variations 0.380726 local health departments 0.450682 geographic area 0.518161 specific geographic area 0.389344 health surveillance programs 0.382617 people 0.378106 epidemiologic study 0.378396 agency gathers information 0.381997 statistically significant excess 0.455543 secondary cancer 0.393665 cancer 0.954313 state cancer registries 0.443891 cancer cluster—that 0.391887 Disease Registry 0.381886 specific time period 0.392616 Toxic Substances 0.380998 cancer death rates 0.436653 cancer incidence 0.401099 Cancer Mortality Maps 0.435229	CLICK HERE
3564	National Cancer Institute	Html	en	The NCI Intramural Research Program	The intramural research program supports projects conducted by scientists located at NCI.	intramural cancer research 0.718907 intramural research program 0.874728 public health issues 0.586317 IRP researchers 0.99482 clinical disciplines 0.535611 basic research discovery 0.633697 cancer initiation 0.556039 NCI offices 0.598153 private sector partners 0.575197 long-term cohort studies 0.573663 NCI intramural research 0.823709 extramural institutions 0.555913 future research 0.545095 clinical trials 0.610273 sophisticated statistical approaches 0.591904 outstanding scientific credentials 0.582191 rare cancers 0.616347 outstanding research 0.546529 clinical IRP researchers 0.677303 extramural investigators 0.808101 basic scientific research 0.670523 cervical cancer 0.590079 traditional funding mechanisms 0.574359 Early-stage clinical trials 0.595705	intramural researchers 0.664665 Cancer Epidemiology 0.564756 population-based research 0.591379 various reasons—to fund 0.579705 National Cancer Program 0.628399 cancer prevention 0.546859 noninfectious virus-like particles 0.5887 relatively little funding 0.573973 cancer research 0.783668 academic institutions 0.606037 high-reward research 0.541951 NCI IRP 0.623146 CCR’s John 0.543838 NIH Clinical Center 0.948229 public health needs 0.603453 Intramural research projects 0.689496 research program complement 0.627977 basic cancer research 0.675487 research resources 0.556851 CCR researcher Ira 0.613887 NCI components 0.59726 CCR colleagues 0.538611 cancer risk 0.53862 federal government investigators 0.655439	CLICK HERE
3569	National Cancer Institute	Html	en	Lung-MAP: Master Protocol for Squamous Cell Lung Cancer	A collection of material about the Lung-MAP study, which will examine treatment outcomes for patients with squamous cell lung cancer assigned to different targeted drugs based on the results of genomic tumor profiling.	Cancer Master Protocol 0.761779 cancer-related genes 0.485085 similar large cancer 0.550307 unique public-private collaboration 0.635287 biomarker-driven clinical trial 0.547514 genomic screening 0.486006 immune system fight 0.473995 lung cancer 0.958963 Cancer Therapy Evaluation 0.548913 National Clinical Trials 0.624831 genomic profile 0.494996 clinical testing 0.479299 U.S. Food 0.476247 advanced squamous cell 0.974568 Squamous cell carcinoma 0.611382 drug nivolumab 0.477374 typical clinical trial 0.556218 patients 0.598987 new investigational treatment 0.557707 single biomarker 0.478327 standard approach 0.479591 current standard 0.486778 drug developers 0.47659 screening tests 0.477882	Drug Administration 0.477451 cancer cells 0.493264 phase II/III trial 0.55125 squamous cell lung 0.99877 Clinical Trials Network 0.627666 precision medicine trial 0.62764 website provides information 0.530495 Cancer Research 0.488908 treatment arm 0.481046 Lung Cancer Master 0.790983 different experimental treatments 0.535025 genomic profiling 0.496642 targeted therapy tests 0.532918 genomic alterations 0.502152 genetic alteration 0.474138 trial arm 0.505132 investigational treatments 0.488936 genetic changes 0.47769 Lung-MAP Launches 0.474509 cell lung cancer 0.935701 treatment options 0.487036 greater likelihood 0.474643 biologics R&D arm 0.540299 new targeted therapies 0.528849	CLICK HERE
17172	National Cancer Institute	Html	es	Hongos medicinales (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de los hongos medicinales como tratamiento para las personas con cáncer.	tumores colorrectales benignos 0.523017 Centro Nacional 0.437112 New Hampshire Avenue 0.425865 Coriolus versicolor 0.603005 Drug Administration 0.41603 NCI Best Case 0.44366 hongo tejado 0.42735 hongos trametes 0.464694 tipo ganoderma 0.427842 datos bibliográficos pubmed 0.427701 siguientes preguntas 0.418216 células t 0.427868 hongos cola 0.470178 siguientes riesgos 0.422485 Instituto Nacional 0.543935 Ganoderma lucidum 0.60047 Salud Complementaria 0.454998 Visuals Online 0.419017	sumario hongos 0.465605 polisacárido -K 0.427899 complementarias revisa 0.427138 Physician Data Query 0.509146 Estados Unidos 0.759861 estadio iii 0.424138 libre uso 0.423898 Lentinus edodes 0.430494 Asia Oriental 0.421328 página manejo 0.417832 ¿El tratamiento 0.429283 inmunitarias llamadas linfocitos 0.447603 ¿Los beneficios 0.416234 juntos cam 0.415492 Series Program 0.416063 medicina complementaria 0.932021 Trametes versicolor 0.613189 tipo cola 0.441661	CLICK HERE
17279	National Cancer Institute	Html	es	Planes para atender un cáncer avanzado	Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado.	tensiones. Algunas personas 0.876955		CLICK HERE